Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
May 31, 2017
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
May 30, 2017
Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA
Lysogene (LYS.PA) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced the completion of enrollment ...
May 30, 2017
Zealand increases its share capital as a consequence of exercise of employee warrants
Copenhagen, May 30, 2017 - Zealand Pharma ("Zealand") has increased its share capital by a nominal amount of DKK 5,000 divided into 5,000 new shares ...
May 30, 2017
Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer
Advaxis, Inc. (ADXS) and Bristol-Myers Squibb (BMY) today announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and Bristol-Myers Squibb’s ...
May 30, 2017
Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737
VANCOUVER, May 30, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics ...
May 30, 2017
ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation
RAMSEY, N.J., May 30, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) announced today that its stockholders voted to approve ADMA’s previously announced acquisition of ...
May 30, 2017
Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
PALO ALTO, Calif., May 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today ...
May 30, 2017
Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update
TEL AVIV, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD) today announced financial results for the three months ended March 31, 2017, and ...
May 30, 2017
Minerva Neurosciences to Present at Jefferies 2017 Healthcare Conference on June 6, 2017
WALTHAM, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat ...
May 25, 2017
Achaogen Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...
May 24, 2017
BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., ...
May 24, 2017
Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product
Lysogene (LYS.PA) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered ...
May 24, 2017
Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
NESS ZIONA, Israel, May 24, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that ...
May 24, 2017
Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017
BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented ...
May 24, 2017
Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting
VANCOUVER , May 24, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response ...
May 24, 2017
TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer
SAN DIEGO, May 24, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
May 23, 2017
Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE's Interleukin Receptor 7 Antagonist
GENEVA & NANTES, France--(BUSINESS WIRE) -- Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of a commercial license agreement that ...
May 23, 2017
Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC
PARIS, May 23, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for ...
May 23, 2017
Albireo Announces Proposed Public Offering of Common Stock
BOSTON, May 23, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
May 23, 2017
Achaogen Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...
Page 109 of 117